La Jolla Pharmaceutical (LJPC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : La Jolla Pharmaceutical (LJPC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Dodgy Ticker who wrote (46)	4/6/1999 10:59:00 AM
From: Harold Engstrom	Read Replies (2) of 66

The company seems to have great potential. It has a committed partner and is pursuing indications with big markets and no effective treatments. It has lots of cash and a burn rate that looks very sustainable. Seemingly, LJP 394 could launch in 2000 for Lupus. Biogen and Idec are pursuing the same indication with what seem to be a similiar approach but with a different compound (anti-CD40L). What does anyone think about LJP being able to execute trials and launch in a timely fashion? Does 2000 seem reasonable? On the face of it, this looks like an excellent risk/reward investment. Does anyone have good arguments against investing in this company?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next